Association between factor V Leiden mutation and coronary artery disease in the northeast region of Turkey

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 8, 2007, Pages 719-722

  Gurlertop, H Yekta ^a   Gundogdu, Fuat ^a,b   Pirim, Ibrahim ^a   Islamoglu, Yahya ^a   Egerci, Nilnur ^a   Sevimli, Serdar ^a   Erdem, Fuat ^a   Senocak, Huseyin ^a  

^a ATATURK UNIVERSITY   (Turkey)

^b ATATÜRK UNIVERSITY   (Turkey)

Author keywords

Coronary angiography; Coronary artery disease; Factor V Leiden

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DNA DETERMINATION; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; TURKEY (REPUBLIC); VENOUS THROMBOEMBOLISM;

ADULT; AGED; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; TURKEY;

EID: 35848934784     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3281139c55     Document Type: Article

References (31)

1. Hooper WC, Dilley A, Ribeiro MJ, Benson J, Austin H, Silva V, et al. A racial difference in the prevalence of the Arg506→Gln mutation. Thromb Res 1996; 81:577-581.
2. Ozawa T, Niiya K, Sakuragawa N. Absence of factor V Leiden in the Japanese. Thromb Res 1996; 81:595-596.
3. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346:1133-1134.
4. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 3:1361-1362.
5. Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conard J, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997; 89:397-402.
6. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90:1004-1008.
7. Gupta N, Khan F, Tripathi M, Singh VP, Tewari S, Ramesh V, et al. Absence of factor V Leiden (G1691A) mutation, FII G20210A allele in coronary artery disease in North India. Indian J Med Sci 2003; 57:535-542.
8. Hobikoglu GF, Akyuz U, Akyuz F, Ozer O, Guney D, Narin A, et al. Factor V leiden is a risk factor for myocardial infarction in young Turkish men. Acta Cardiol 2004; 59:594-597.
9. Lindblad B, Svensson PJ, Dahlback B. Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C [letter]. Lancet 1994; 343:917.
10. Holm J, Zoller B, Svensson PJ, Berntorp E, Erhardt L, Dahlback B. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 1994; 344:952-953.
11. Marz W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease [letter]. Lancet 1995; 345:526.
12. Kontula K, Ylikorkala A, Miettinen H, Vuorio A, Kauppinen-Makelin R, Hamalainen L, et al. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995; 73:558-560.
13. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332:912-917.
14. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, et al. Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance [letter]. Lancet 1995; 345:321.
15. van Bockxmeer FM, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V [letter]. Nat Med 1995; 1:185.
16. Ardissino D, Peyvandi F, Merlini PA, Colombi E, Mannucci PM. Factor V (Arg 506→Gln) mutation in young survivors of myocardial infarction. Thromb Haemost 1996; 75:701-702.
17. Takamiya O, Ishida F, Kodaira H, Kitano K. APC-resistance and Mnl I genotype (Gln 506) of coagulation factor V are rare in Japanese population [letter]. Thromb Haemost 1995; 74:996.
18. Baykan M, Celik S, Ucar F, Kaplan S, Ovali E, Erdol C. Effects of factor V Leiden mutations on prognosis in patients with acute myocardial infarction [in Turkish]. Anadolu Kardiyol Derg 2001; 1:242-245; AXIV.
19. Gurgey A, Mesci L. The prevalence of factor V Leiden (1691 G→A) mutation in Turkey. Turk J Pediatr 1997; 39:313-315.
20. Mizuno K, Satomura K, Miyamoto A, Arakawa K, Shibuya T, Arai T, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326:287-291.
21. DiSciascio G, Cowley MJ, Goudreau E, Vetrovec GW, Johnson DE. Histopathologic correlates of unstable ischemic syndromes in patients undergoing directional coronary atherectomy: in vivo evidence of thrombosis, ulceration, and inflammation. Am Heart J 1994; 128:419-426.
22. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89:2817-2821.
23. Mansourati J, Da Costa A, Munier S, Mercier B, Tardy B, Ferec C, et al. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost 2000; 83:822-825.
24. Cushman M, Rosendaal FR, Psaty BM, Cook EF, Valliere J, Kuller LH, et al. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost 1998; 79:912-915.
25. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: the Copenhagen City Heart Study and 2 meta-analyses. Blood 2002; 100:3-10.
26. Gardemann A, Arsic T, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The factor II G20210A and factor V G1691A gene transitions and coronary heart disease. Thromb Haemost 1999; 81:208-213.
27. Eitzman DT, Westrick RJ, Shen Y, Bodary PF, Gu S, Manning SL, et al. Homozygosity for factor V Leiden leads to enhanced thrombosis and atherosclerosis in mice. Circulation 2005; 111:1822-1825.
28. Donmez Y, Kanadasi M, Tanriverdi K, Demir M, Demirtas M, Cayli M, et al. Prothrombin 20210GA and factor V Leiden mutations in patients less than 55 years old with myocardial infarction. Jpn Heart J 2004; 45:505-512.
29. Demarmels Biasiutti F, Merlo C, Furlan M, Sulzer I, Binder BR, Lammle B. No association of APC resistance with myocardial infarction. Blood Coagul Fibrinolysis 1995; 6:456-459.
30. Samani NJ, Lodwick D, Martin D, Kimber P. Resistance to activated protein C and risk of premature myocardial infarction. Lancet 1994; 344:1709-1710.
31. Lander ES, Schork NJ. Genetic dissection of complex traits [review]. Science 1994; 265:2037-2048; erratum 266:353.